Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to $1.1 million.

  • Arcadia Biosciences' Cash & Equivalents fell 7154.47% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 7154.47%. This contributed to the annual value of $4.2 million for FY2024, which is 3491.87% down from last year.
  • As of Q3 2025, Arcadia Biosciences' Cash & Equivalents stood at $1.1 million, which was down 7154.47% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, Arcadia Biosciences' Cash & Equivalents peaked at $44.0 million during Q2 2021, and registered a low of $1.1 million during Q3 2025.
  • Over the past 5 years, Arcadia Biosciences' median Cash & Equivalents value was $13.5 million (recorded in 2023), while the average stood at $16.1 million.
  • As far as peak fluctuations go, Arcadia Biosciences' Cash & Equivalents skyrocketed by 24826.0% in 2021, and later crashed by 8557.83% in 2024.
  • Over the past 5 years, Arcadia Biosciences' Cash & Equivalents (Quarter) stood at $28.7 million in 2021, then decreased by 28.03% to $20.6 million in 2022, then crashed by 68.43% to $6.5 million in 2023, then tumbled by 34.92% to $4.2 million in 2024, then tumbled by 73.6% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.4 million for Q2 2025, and $3.2 million during Q1 2025.